Nothing dramatic broke in the last day or two. The stocks barely moved — Compass Pathways down a whisker, atai up a touch, MindMed up about two percent. No news drove any of it. What today's data actually shows is a field holding its breath. The freshest real thread is the countdown to Cybin's results for CYB003, its version of psilocybin (the active ingredient in magic mushrooms, slightly changed so it lasts more evenly in the body) being tested against major depression. Our swarm of forecasting agents expects that result within roughly ten to eleven weeks. Most agents think it will show the drug works — but they also warn that reviewers will raise the same old question: in these trials, patients often can feel whether they got the real drug or a fake pill, because the real one causes noticeable effects. That makes it harder to prove the benefit is real and not just belief.
Beneath the news sits a single, honest tension. This whole field is now leaning on data it does not yet have. One company's result has quietly become the test everyone reads as a signal for everything else — if Cybin's works, forecasters expect Compass and atai shares to rise in sympathy too, treating it as proof the broader mushroom-medicine idea holds. That is the deeper current: the science is maturing to the point where a single clean result can move the whole story forward, or stall it. The highest trajectory here is not hype. It is that this next result is measured carefully, the honest questions about blinding get answered in the open, and the field earns its progress rather than borrowing it.
At the same time, another quieter thread keeps moving. Because a president has spoken about ibogaine — a plant medicine some veterans travel abroad to try for trauma and addiction — forecasters expect at least one more state to announce funding or a small pilot program within about ten weeks, using veteran care as the reason. They also expect a cautious safety article to appear soon, warning that ibogaine can strain the heart. Both things are true at once, and both belong in the picture.
For the real people inside this story, the stakes are simple and heavy. A veteran who has tried everything for the nightmares that will not stop. A person whose depression has not lifted despite years of pills. They are not watching stock tickers. They are waiting to hear whether a new door might actually open, and whether it will be safe when it does. The most positive thing that could genuinely happen from here is not a headline. It is that the coming results are clear and honest, the safety questions are met head-on, and one more state quietly builds a real path to care. That is progress that lasts.
What is being called in cannot be called back. The currents forming in legislation, in research, in culture — OOTW reads them daily, so you don't have to navigate them alone.
What is forming beneath the surface is always closer than it appears.
62%
Drug enforcement agency's weed stance will shape psychedelic policy too
The DEA (Drug Enforcement Administration — the US agency that controls which drugs are legal and illegal) has been filing its final arguments in marijuana scheduling hearings, and those arguments show the agency still strongly opposes loosening drug rules. Within the next 10 weeks, that same resistant tone is expected to show up in official comments about rescheduling psilocybin (magic mushrooms) and ibogaine. This matters because the DEA's attitude can slow or block drugs from moving to a less restricted legal category, even when there's medical evidence supporting them.
→ The DEA looks set to officially oppose relaxing psychedelic drug rules, which could slow down every path to legal psychedelic therapy.
Resolves: 2026-10-27 · USA
POLICY
the precise call ▾
DEA's marijuana final briefs signal continued opposition posture that gets explicitly extended to psychedelic scheduling commentary within 10 weeks.. The final briefs reveal enforcement's institutional stance. That opposition framing carries over directly to any psilocybin/ibogaine scheduling discussion.
60%
Cybin's mushroom-derived drug works in trial but faces credibility questions
Cybin, a psychedelic medicine company, is running a large clinical trial of CYB003 — a modified version of psilocin, the active ingredient in magic mushrooms — for people with major depression. Within 11 weeks, the company is expected to announce results showing the drug actually works. But experts reviewing the data for the FDA (the US Food and Drug Administration, which decides whether new medicines can be sold) are likely to raise a specific worry: participants can probably tell whether they got the real drug or a placebo because the psychedelic experience itself is a giveaway, which makes the results harder to trust.
→ Cybin's depression drug will likely show it works, but experts will immediately question whether the trial design was strong enough to prove it.
Resolves: 2026-11-03 · USA
CLINICAL
the precise call ▾
Cybin's CYB003 Phase 3 MDD interim/topline readout hits its primary efficacy endpoint but FDA-facing analysts flag functional unblinding concerns within 11 weeks.. Deuterated psilocin still produces perceptual effects; blinding integrity is the recurring reviewer concern across all psychedelic NDAs. Efficacy likely; methodological caveats inevitable.
57%
Cybin's depression drug trial results expected in about 10 weeks
Multiple independent experts — including people who think like FDA reviewers, academic researchers, and investors — agree that Cybin will announce results from its large depression trial within 10 to 11 weeks, and those results will likely show the drug works. However, the announcement will almost certainly come with footnotes: questions about whether patients could tell they were on the real drug, and whether the drug behaved consistently in different people's bodies. These caveats could affect how seriously regulators take the findings.
→ Expect Cybin to announce promising depression trial results within 11 weeks, alongside legitimate scientific questions that regulators will need to resolve.
Resolves: 2026-11-16 · Global
CLINICAL
the precise call ▾
Cybin CYB003 (deuterated psilocin) delivers a dated MDD topline within 10-11 weeks showing efficacy but carrying blinding/PK methodological caveats.. Consensus of 4 agents: fda_reviewer, maps_researcher, investor. 0 dissenting.
57%
Positive trial results could make Cybin's stock jump 15% in one day
When Cybin announces that CYB003 worked in its depression trial — which is expected within 10 weeks — the stock market is likely to react strongly. A single-day jump of more than 15% in Cybin's share price (ticker: CYBN) is considered a real possibility because good trial results reduce the risk that the drug fails, and investors reward that. The modified chemistry of CYB003 was specifically designed to make the drug more predictable and consistent in the body, which strengthens the case that the results are reliable.
→ If Cybin's trial results are positive, expect the company's stock to jump sharply — which would signal real investor confidence in this new class of depression treatment.
Resolves: 2026-10-27 · Global
CLINICAL
the precise call ▾
Cybin reports positive CYB003 topline in MDD, driving a >15% single-day CYBN share move within 10 weeks.. Deuteration improves PK consistency and prior CYB003 signals were strong. Positive topline is a genuine de-risking catalyst the market will reward.
60%
A major investigation will warn about ibogaine's heart risks within 8 weeks
Ibogaine is a powerful psychedelic derived from an African plant that has shown promise for treating opioid addiction, and it recently got high-profile political attention. Whenever a president or major political figure promotes a drug, journalists and scientists tend to publish a hard-hitting counter-story — and ibogaine has a well-documented risk of causing dangerous heart rhythm problems that can be fatal. Within 8 weeks, expect a major investigation or feature article to spotlight these cardiac dangers as a reality check on the excitement.
→ A major warning about ibogaine's potentially fatal heart risks is coming soon, and it will balance out the recent political hype around the drug.
Resolves: 2026-10-13 · Global
RESEARCH
the precise call ▾
A skeptical ibogaine cardiac-safety (QT/torsades) investigation or feature publishes as counterweight to Trump hype within 8 weeks.. Every presidential drug endorsement triggers a safety-desk rebuttal. Ibogaine's known cardiotoxicity is the obvious peg. I'd write it myself.